Rescue of silenced UCHL1 and IGFBP4 expression suppresses clonogenicity of giant cell tumor-derived stromal cells

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 61-67

  Fellenberg, Jörg ^a   Sähr, Heiner ^a   Liu, Li ^b   Schönsiegel, Frank ^b   Depeweg, Daniela ^a   Lehner, Burkhard ^a   Herr, Ingrid ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Epigenetic silencing; Giant cell tumor; IGFBP4; Mesenchymal stem cell; Promoter hypermethylation; UCHL1

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; SOMATOMEDIN BINDING PROTEIN 4; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; GIANT CELL TUMOR; HUMAN; HUMAN CELL; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 4 GENE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STROMA CELL; UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1 GENE;

CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GIANT CELL TUMORS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; OCTAMER TRANSCRIPTION FACTOR-3; SOXB1 TRANSCRIPTION FACTORS; STROMAL CELLS; UBIQUITIN THIOLESTERASE;

EID: 84878963378     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.011     Document Type: Article

References (38)

1. Wulling M., Engels C., Jesse N., Werner M., Delling G., Kaiser E. The nature of giant cell tumor of bone. J. Cancer Res. Clin. Oncol. 2001, 127:467-474.
2. Zheng M.H., Robbins P., Xu J., Huang L., Wood D.J., Papadimitriou J.M. The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol. Histopathol. 2001, 16:297-307.
3. Becker W.T., Dohle J., Bernd L., Braun A., Cserhati M., Enderle A., Hovy L., Matejovsky Z., Szendroi M., Trieb K., Tunn P.U. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J. Bone Joint Surg. Am. 2008, 90:1060-1067.
4. Gamberi G., Benassi M.S., Bohling T., Ragazzini P., Molendini L., Sollazzo M.R., Merli M., Ferrari C., Magagnoli G., Bertoni F., Picci P. Prognostic relevance of C-myc gene expression in giant-cell tumor of bone. J. Orthop. Res. 1998, 16:1-7.
5. Osaka S., Toriyama M., Taira K., Sano S., Saotome K. Analysis of giant cell tumor of bone with pulmonary metastases. Clin. Orthop. Relat. Res. 1997, 253-261.
6. Atkins G.J., Haynes D.R., Graves S.E., Evdokiou A., Hay S., Bouralexis S., Findlay D.M. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J. Bone Miner. Res. 2000, 15:640-649.
7. Burmester G.R., Winchester R.J., Dimitriu-Bona A., Klein M., Steiner G., Sissons H.A. Delineation of four cell types comprising the giant cell tumor of bone. Expression of Ia and monocyte-macrophage lineage antigens. J. Clin. Invest. 1983, 71:1633-1648.
8. Goldring S.R., Schiller A.L., Mankin H.J., Dayer J.M., Krane S.M. Characterization of cells from human giant cell tumors of bone. Clin. Orthop. Relat. Res. 1986, 59-75.
9. Robinson D., Segal M., Nevo Z. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. Pathobiology 2002, 70:333-342.
10. Wulling M., Delling G., Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum. Pathol. 2003, 34:983-993.
11. Fellenberg J., Lehner B., Witte D. Silencing of the UCHL1 gene in giant cell tumors of bone. Int. J. Cancer 2010, 127:1804-1812.
12. Das P.M., Singal R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22:4632-4642.
13. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
14. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000, 16:168-174.
15. Haynesworth S.E., Baber M.A., Caplan A.I. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992, 13:69-80.
16. Reyes M., Lund T., Lenvik T., Aguiar D., Koodie L., Verfaillie C.M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001, 98:2615-2625.
17. Forsyth R.G., De Boeck G., Bekaert S., De Meyer T., Taminiau A.H., Uyttendaele D., Roels H., Praet M.M., Hogendoorn P.C. Telomere biology in giant cell tumour of bone. J. Pathol. 2008, 214:555-563.
18. Kirkpatrick K.L., Clark G., Ghilchick M., Newbold R.F., Mokbel K. HTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur. J. Surg. Oncol. 2003, 29:321-326.
19. Xu D., Gruber A., Peterson C., Pisa P. Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br. J. Haematol. 1998, 102:1367-1375.
20. Oreffo R.O., Marshall G.J., Kirchen M., Garcia C., Gallwitz W.E., Chavez J., Mundy G.R., Bonewald L.F. Characterization of a cell line derived from a human giant cell tumor that stimulates osteoclastic bone resorption. Clin. Orthop. Relat. Res. 1993, 229-241.
21. Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int. Orthop. 2006, 30:484-489.
22. Fellenberg J., Saehr H., Lehner B., Depeweg D. A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cells. Cancer Lett. 2012, 321:162-168.
23. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
24. Nguyen C., Liang G., Nguyen T.T., Tsao-Wei D., Groshen S., Lubbert M., Zhou J.H., Benedict W.F., Jones P.A. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J. Natl. Cancer Inst. 2001, 93:1465-1472.
25. Brenet F., Moh M., Funk P., Feierstein E., Viale A.J., Socci N.D., Scandura J.M. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS ONE 2011, 6:e14524.
26. Easwaran H., Johnstone S.E., Van Neste L., Ohm J., Mosbruger T., Wang Q., Aryee M.J., Joyce P., Ahuja N., Weisenberger D., Collisson E., Zhu J., Yegnasubramanian S., Matsui W., Baylin S.B. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome. Res. 2012, 22:837-849.
27. Kim J., Chu J., Shen X., Wang J., Orkin S.H. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008, 132:1049-1061.
28. Schoenhals M., Kassambara A., De Vos J., Hose D., Moreaux J., Klein B. Embryonic stem cell markers expression in cancers. Biochem. Biophys. Res. Commun. 2009, 383:157-162.
29. Okochi-Takada E., Nakazawa K., Wakabayashi M., Mori A., Ichimura S., Yasugi T., Ushijima T. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int. J. Cancer 2006, 119:1338-1344.
30. Tokumaru Y., Yamashita K., Osada M., Nomoto S., Sun D.I., Xiao Y., Hoque M.O., Westra W.H., Califano J.A., Sidransky D. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004, 64:5982-5987.
31. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., Hruban R.H., Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003, 63:3735-3742.
32. Yu J., Tao Q., Cheung K.F., Jin H., Poon F.F., Wang X., Li H., Cheng Y.Y., Rocken C., Ebert M.P., Chan A.T., Sung J.J. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 2008, 48:508-518.
33. Mani A., Gelmann E.P. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 2005, 23:4776-4789.
34. Durai R., Davies M., Yang W., Yang S.Y., Seifalian A., Goldspink G., Winslet M. Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int. J. Oncol. 2006, 28:1317-1325.
35. Leng S.L., Leeding K.S., Whitehead R.H., Bach L.A. Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Mol. Cell Endocrinol. 2001, 174:121-127.
36. Park J.H., Corkins M.R., Vanderhoof J.A., Caruso N.M., Hrbek M.J., Schaffer B.S., Slentz D.H., McCusker R.H., MacDonald R.G. Expression of insulin-like growth factor-II and insulin-like growth factor binding proteins during Caco-2 cell proliferation and differentiation. J. Cell Physiol. 1996, 166:396-406.
37. Culouscou J.M., Shoyab M. Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res. 1991, 51:2813-2819.
38. Damon S.E., Maddison L., Ware J.L., Plymate S.R. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 1998, 139:3456-3464.